Among the patients with type 2 diabetes (n = 34), 21 (61.8%) were treated with metformin, 8 (23.5%) with insulin, 6 (17.6%) with DPP-4 inhibitors, and 2 (5.9%) with sulfonylureas. Here, DPP4 is linked to type 2 diabetes mellitus.